NCT03903705 2025-04-06
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
Hutchmed
Innovent Biologics (Suzhou) Co. Ltd.
Beijing Friendship Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.